| Literature DB >> 32968175 |
Mingwei Shao1,2,3, Changli Sun1,3, Xiaoxiao Liu1,3, Xiaoxue Wang1,2,3, Wenli Li4,5, Xiaoyi Wei6, Qinglian Li7,8, Jianhua Ju9,10,11.
Abstract
Fungal-bacterial associations are present in nature, playing important roles in ecological, evolutionary and medicinal processes. Here we report a fungus-bacterial symbiont from marine sediment. The bacterium lives inside the fungal mycelium yet is robust enough to survive independent of its host; the independently grown bacterium can infect the fungal host in vitro and continue to grow progenitively. The bacterial symbiont modulates the fungal host to biosynthesize a polyketide antimicrobial,Entities:
Mesh:
Substances:
Year: 2020 PMID: 32968175 PMCID: PMC7511336 DOI: 10.1038/s42003-020-01239-y
Source DB: PubMed Journal: Commun Biol ISSN: 2399-3642
Fig. 1Morphological identification of symbiont F190/B001.
a–c The morphology of the symbiont F190/B001 on the ISP2 plate. d–e The morphology of arthrospore and mycelium under optical microscope (400*). f–h The morphology of the symbiont F190/B001 mycelium after growth on the ISP2 plate (without antibiotics) for 7 days shows a filamentous septate hyaline to brown hyphae with a section able to form the spore. i The morphology of spore, which shows the spore is septate, cylindrical, and straight. j–m Mycelium and spore of symbiont F190/B001 were stained with SYTO 9 and observed using a Leica TCS SP8 AOBS Laser Microscope at 510/520 nm (fluorescence mode). Green fluorescence in the fungal hyphae or arthrospore indicates that the mycelia harbored a large number of alive endobacteria. n–o Fluorescent in situ hybridization (FISH) micrographs of symbiont F190/B001 mycelium observed using a Leica TCS SP8 AOBS Laser Microscope at 515/530 nm (fluorescence mode). p–q Confocal Laser Scanning micrographs of symbiont F190/B001 mycelium after coculture with GFP-Labeled endobacterium A. faecalis SCSIO B001. The fungal hyphae or spore contain a rod-shaped GFP-labeled endobacterium (fluorescence mode). Scale bar, 1 µm.
Fig. 2Fungal production of spiromarmycin (1) is triggered by endobacterium.
a The structure of spiromarmycin (1). b X-ray structure of spiromarmycin (1). c HPLC analyses of the PDA fermentation butanone extracts. (i: negative controls of the symbiont F190/B001; ii: symbiont F190/B001 treated with ampicillin; iii symbiont F190/B001 treated with kanamycin; iv: symbiont F190/B001 treated with chloromycetin; v: symbiont F190/B001 treated with ciprofloxacin; v: symbiont F190/B001 after treated with four kinds of antibiotics and retrained on a ISP2 plate containing ciprofloxacin hydrochloride consecutively; vii: symbiont F190/B001 precipitate out the irregular brown plaques; viii: purified compounds spiromarmycin; ix: A. faecalis SCSIO B001; mAU, milliabsorbance units).
Selected MIC values of spiromarmycin (1) against prokaryotic and Candida albicans(in μg/mL).
| Organism | Source | MIC (μg/mL) |
|---|---|---|
| Clinically resistant bacteria | 4.0 | |
| MRSA /methicillin-resistant | Clinically resistant bacteria | 16.0 |
| Poultry pathogen | 16.0 | |
| Algicidal bacteria | 32.0 | |
| Clinically resistant bacteria | 16.0 | |
| Clinically resistant bacteria | 16.0 | |
| Clinically resistant bacteria | 8.0 | |
| Clinically resistant bacteria | 16.0 | |
| Clinically resistant bacteria | 128.0 | |
| Clinically resistant bacteria | 128.0 | |
| Clinically resistant strain | 16.0 | |
| Clinically resistant strain | 2.0 | |
| Clinically resistant strain | 1.0 |
IC50 Values for spiromarmycin activity against eukaryotic microorganisms (in μg/mL)a.
| Phytopathogen | Spiromarmycin | Cycloheximideb | Metalaxylb | Dimethomorphb |
|---|---|---|---|---|
| 3.2 ± 0.6 | 0.3 ± 0.0 | NT | NT | |
| 4.3 ± 1.1 | 0.3 ± 0.0 | NT | NT | |
| 5.7 ± 0.3 | 3.3 ± 0.2 | NT | NT | |
| 8.1 ± 0.5 | 2.6 ± 0.1 | NT | NT | |
| >50 ± 0 | 0.9 ± 0.1 | NT | NT | |
| 1.2 ± 0.1 | 4.4 ± 0.2 | NT | NT | |
| 5.0 ± 0.4 | 2.3 ± 0.3 | NT | NT | |
| >50 ± 0 | 10.6 ± 1.0 | NT | NT | |
| >50 ± 0 | 1.7 ± 0.1 | NT | NT | |
| >50 ± 0 | 4.9 ± 0.2 | NT | NT | |
| >50 ± 0 | >50 ± 0 | NT | NT | |
| 17.1 ± 0.8 | 28.8 ± 8.7 | NT | NT | |
| >50 ± 0 | 4.3 ± 0.7 | NT | NT | |
| 3.5 ± 0.6 | 1.9 ± 0.9 | NT | NT | |
| 1.8 ± 0.6 | 0.8 ± 0.3 | NT | NT | |
| 1.7 ± 1.1 | 0.02 ± 0.0 | NT | NT | |
| >50 ± 0 | 8.5 ± 0.9 | NT | NT | |
| >50 ± 0 | >50 ± 0 | NT | NT | |
| 8.1 ± 0.7 | NT | 38.7 ± 5.9 | 0.09 ± 0.0.02 | |
| 4.5 ± 0.3 | NT | 1.4 ± 0.1 | 0.6 ± 0.2 | |
| 1.5 ± 0.3 | NT | 11.1 ± 1.5 | 0.5 ± 0.04 |
NT No tested.
aValues represent the mean of three replications ± standard deviation.
bCycloheximide was coassayed as a positive control.
Fig. 3Postulated biosynthesis of spiromarmycin (1).
a Genetic organization of the spiromarmycin biosynthetic gene cluster. b According to the 13C-labeling experimental results and bioinformatics analysis, we propose a reasonable biosynthetic pathway of spiromarmycin.
Fig. 4Model for mutualistic associations of symbiont SCSIO F190/B001.
The endobecteria A. faecali SCSIO B001 can be released from the fugal host cell and infect the fungal host cells in vitro and continue to grow progenitive; endobecteria A. faecali SCSIO B001 can also enter the vegetative fungal spores and are transferred to the next generation. The endobecteria modulates fungal host to produce the broad spectrum antimicrobial spiromarmycin, which can help the symbiont drive away the surrounding microbes (prokaryotic or eukaryotic microorganisms) to gain more living conditions in marine enviroment.